Nortiva Bio Launches to Develop Long-Acting Oral Medicines
Nortiva Bio, Inc. (âNortivaâ) today announced its launch as a clinical-stage biopharmaceutical company dedicated to developing long-acting oral medicines u
INVA - Innoviva, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$37.00
DETAILS
HIGH:
$42.00
LOW:
$32.00
MEDIAN:
$37.00
CONSENSUS:
$37.00
UPSIDE:
67.69%
Stock News
Nortiva Bio Launches to Develop Long-Acting Oral Medicines
LEXINGTON, Mass.--(BUSINESS WIRE)--Nortiva Bio, Inc. (“Nortiva”) today announced its launch as a clinical-stage biopharmaceutical company dedicated to developing long-acting oral medicines using its proprietary LYNX™ drug delivery platform. Nortiva's LYNX platform can transform daily pills into long-acting oral therapies with single doses that last up to a month in multiple therapeutic areas. This advancement can optimize efficacy and safety, improve medication adherence, and positively impact.
Innoviva Specialty Therapeutics Announces Distribution and Licensing Agreement with Dr. Reddy's for XACDURO® in Select International Markets
WALTHAM, Mass.--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (Nasdaq: INVA), today announced that it has entered into an exclusive distribution and licensing agreement with Dr. Reddy's Laboratories Ltd., a global pharmaceutical company, for the development and commercialization of XACDURO® (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use, in South and Central America, the Caribbean, Russia and Commonwealth of Independent S.
Innoviva, Inc. (INVA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Innoviva, Inc. (INVA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Innoviva to Participate in Upcoming Investor Conferences
Innoviva, Inc. (NASDAQ: INVA) (âInnovivaâ or the âCompanyâ), a diversified biopharmaceutical company with a core royalties portfolio, a leading critica
Innoviva to Participate in Upcoming Investor Conferences
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets, today announced that management will participate in the following upcoming investor conferences in June: Goldman Sachs 47th Annual Global Healthcare Conference.
Innoviva Stock Is Up Just 10% This Past Year. Here's Why a Fund Bought $2.5 Million More
Innoviva develops respiratory pharmaceuticals through strategic partnerships and royalty agreements in the global healthcare market.
Innoviva (INVA) Tops Q1 Earnings Estimates
Innoviva (INVA) came out with quarterly earnings of $0.44 per share, beating the Zacks Consensus Estimate of $0.43 per share. This compares to earnings of $0.25 per share a year ago.
Innoviva Reports First Quarter 2026 Financial Results; Highlights Recent Company Progress
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets, today reported financial results for the first quarter ended March 31, 2026, and highlighted select corporate progress and achievements. “We delivered a strong.
Merck (MRK) Reports Q1 Loss, Tops Revenue Estimates
Merck (MRK) came out with a quarterly loss of $1.28 per share versus the Zacks Consensus Estimate of a loss of $1.51. This compares to earnings of $2.22 per share a year ago.
Innoviva, Inc. (NASDAQ:INVA) Given Consensus Recommendation of “Moderate Buy” by Brokerages
Shares of Innoviva, Inc. (NASDAQ: INVA - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the seven brokerages that are covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to
3 Bargain-Cheap Small Caps Worth a Second Look
The price-to-earnings (P/E) ratio is a commonly used metric that provides a snapshot of a company's valuation. The average P/E ratio of stocks in the S&P 500 is around 27X.
Innoviva (NASDAQ:INVA) Shares Cross Above 200 Day Moving Average – Here’s What Happened
Innoviva, Inc. (NASDAQ: INVA - Get Free Report)'s stock price passed above its two hundred day moving average during trading on Monday. The stock has a two hundred day moving average of $20.50 and traded as high as $23.15. Innoviva shares last traded at $23.02, with a volume of 450,806 shares. Analyst Upgrades and Downgrades
Analysts Set Innoviva, Inc. (NASDAQ:INVA) Price Target at $34.80
Shares of Innoviva, Inc. (NASDAQ: INVA - Get Free Report) have earned a consensus rating of "Moderate Buy" from the seven research firms that are presently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and five have assigned a buy recommendation to
Innoviva Specialty Therapeutics Earns Strong Performance Rating in Access to Medicine Foundation's 2026 Antimicrobial Resistance Benchmark Report
WALTHAM, Mass.--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, a subsidiary of Innoviva Inc., today announced that its infectious disease therapeutic portfolio earned a strong performance rating of 80% in the 2026 Antimicrobial Resistance (AMR) Benchmark Report published by the Access to Medicine Foundation. The score represents the highest rating in the small- and medium-sized enterprise (SME) category, achieved by only one other company in this year's report. The AMR Benchmark evaluates ph.
Innoviva, Inc. (INVA) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference Transcript
Innoviva, Inc. (INVA) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference Transcript
Innoviva, Inc. (NASDAQ:INVA) Receives Average Recommendation of “Moderate Buy” from Brokerages
Innoviva, Inc. (NASDAQ: INVA - Get Free Report) has been given an average recommendation of "Moderate Buy" by the eight ratings firms that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating on the
Innoviva Reports Fourth Quarter and Full Year 2025 Financial Results; Highlights Recent Company Progress
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets, today reported financial results for the fourth quarter and full year ended December 31, 2025, and highlighted select corporate progress and achievements. “202.
Innoviva to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets, today announced that management will participate in a fireside chat at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 26, 2026 at.
SG Americas Securities LLC Raises Position in Innoviva, Inc. $INVA
SG Americas Securities LLC grew its position in shares of Innoviva, Inc. (NASDAQ: INVA) by 134.4% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 49,079 shares of the biotechnology company's stock after buying an additional 28,141 shares during the
Price Targets
Innoviva price target raised to $42 from $35 at BTIG
$42.00
(was $23.49)
BTIG
Inova Technology, Inc. (INVA) PT Raised to $32 at Cantor Fitzgerald on Improved Outlook
$32.00
(was $23.98)
Steve Seedhouse
·
Cantor Fitzgerald
Innoviva initiated with a Buy at BTIG
$35.00
(was $22.70)
BTIG
Innoviva price target raised to $46 from $45 at H.C. Wainwright
$46.00
(was $20.14)
H.C. Wainwright
Innoviva initiated with a Sell at Goldman Sachs
$17.00
(was $19.03)
Goldman Sachs
This Arm Holdings Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Monday
$35.00
(was $19.93)
Trevor Allred
·
Oppenheimer
Innoviva initiated with an Outperform at Scotiabank
$55.00
(was $17.64)
Scotiabank
Morgan Stanley Maintains Underweight on Innoviva, Raises Price Target to $13
$13.00
(was $14.72)
Morgan Stanley
Morgan Stanley Maintains Underweight on Innoviva, Lowers Price Target to $12
$12.00
(was $14.37)
Morgan Stanley